Inventiva announced improved financial results for the first half of 2026, reducing its net loss to €69.5 million from €175.9 million the previous year. The company completed the final patient visit in its Phase 3 NATiV3 trial for MASH, with topline results expected in Q4 2026. Inventiva holds €166.1 million in cash and €67.8 million in short-term deposits, but notes financing risks as current cash alone won't cover a full year of operations. If additional financing is secured, the company could extend its runway into early 2028 and aims for regulatory submission in H1 2027 with a potential U.S. launch in 2028.
Inventiva's recent update includes a net loss reduction to €69.5 million in H1 2026 and ongoing Phase 3 trial progress. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 30, 2026 00:12 WIB: out of 100 priced US health stocks, 23 rose and 76 fell. Notable movers include ABCL at USD 14.53 with 71% buy orders, INO at USD 1.12 with 80% buy orders, and XRAY at USD 8.96 with 100% buy orders and a typical hold time of 71 days.
Precision Optics Corporation reported a strong Q4 with record revenue of $8.8 million, a 42% increase year-over-year, surpassing analyst estimates of $7.1 million. The company also beat EPS expectations, posting -$0.01 versus the predicted -$0.06, si...
Analyst firm Craig-Hallum adjusted Boot Barn Holdings' price target to $224, an 84.91% increase from its recent stock price of $121.14, reflecting strong growth potential. The company aims to expand merchandise margins by 60 basis points in fiscal 20...
Jabil is set to report its Q4 earnings on September 30, 2026, with analysts expecting earnings per share around $4.07 and revenue near $9.71 billion, marking a 16.5% revenue increase year-over-year. The company is benefiting from robust growth in AI ...
Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...
Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while th...
